Global News

23andMe, Pfizer to research genetics of inflammatory bowel disease

Wednesday, August 13, 2014 01:15 PM

23andMe, a California-based personal genetics company, and Pfizer have inked a research agreement in which the companies aim to enroll 10,000 people with inflammatory bowel disease (IBD) in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD.

More... »

WIRB Copernicus Group

uniQure acquires cardiology gene therapy company InoCard

Wednesday, August 13, 2014 01:11 PM

uniQure, an Amsterdam, Netherlands-based provider of human gene therapy, has acquired InoCard, a Germany-based early-stage biotechnology company focused on the development of gene therapy approaches for cardiac disease.

More... »


U.S. research institutions collaborate to share, standardize neuroscience databases

Wednesday, August 13, 2014 01:04 PM

The Allen Institute for Brain Science based in Seattle, Wash., the California Institute of Technology, the New York University School of Medicine, the Howard Hughes Medical Institute (HHMI) in Massachusetts and the University of California, Berkeley are collaborating on a project aimed at making databases about the brain more useable and accessible for neuroscientists—a step seen as critical to accelerating the pace of discoveries about the brain in health and disease.

More... »

Cellular Biomedicine Group acquires Agreen Biotech

Wednesday, August 13, 2014 01:01 PM

Cellular Biomedicine Group, a California-based developer of new treatments for degenerative and cancerous diseases, has acquired China-based Agreen Biotech and its founder’s U.S. patent for $3.28 million in cash, the issuance of 753,522 shares of CBMG common stock and the issuance of 75,000 shares of CBMG restricted stock units.

More... »

Oncothyreon acquires Alpine Biosciences

Wednesday, August 13, 2014 12:59 PM

Oncothyreon, a Washington-based biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, has acquired Alpine Biosciences, a Seattle, Wash.-based privately held biotechnology company developing protocells, a nanoparticle platform technology designed to enable the targeted delivery of multiple therapeutic agents, including nucleic acids, proteins, peptides and small molecules. 

More... »

Galenica lays foundation for two listed, independent companies

Wednesday, August 13, 2014 12:57 PM

The Galenica Group, a Switzerland-based healthcare group that develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks, plans to separate into two independent companies.

More... »

Huron Consulting Group launches clinical trial data analytics and visualization service

Wednesday, August 13, 2014 12:55 PM

Huron Consulting Group, a Chicago, Ill.-based provider of business consulting services, has launched its trialRx service, a Huron Life Sciences clinical trial data monitoring service to help pharma, biotech and device companies understand and mitigate clinical trial disclosure risks.

More... »

Daiichi Sankyo, Charleston Laboratories collaborate on hydrocodone products for pain

Monday, August 11, 2014 01:45 PM

Daiichi Sankyo and Charleston Laboratories, through its wholly owned subsidiary LOCL Pharma, have entered into a strategic collaboration for the development and U.S. commercialization of Charleston Laboratories’ novel hydrocodone combination products, including CL-108, being studied for the treatment of moderate to severe acute pain as well as the reduction of opioid-induced nausea and vomiting (OINV).

More... »

Venn Life Sciences acquires French CRO Cardinal Systems

Monday, August 11, 2014 01:42 PM

Venn Life Sciences, a growing CRO providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, has acquired Cardinal Systems, a France-based CRO specializing in data management and randomization systems.

More... »

Sanofi licenses Immune Design's GLAAS platform to treat food allergies

Monday, August 11, 2014 01:38 PM

Sanofi and Immune Design, a clinical-stage immunotherapy company, have entered into a licensing agreement for use of Immune Design's GLAAS discovery platform to develop therapeutic agents to treat a selected food allergy.

More... »

`
CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

August 18

Ebola outbreak highlights need to improve biosafety, infrastructure to handle future health emergencies

More African American professional women open to participating in medical research

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs